Healthcare entity
All 1 tracked stories fall under one category: medical-devices. Of the tracked stories, 1 of 1 also mention Glaukos Corporation, the most common co-covered peer. The tracked stories average 5 original sources each. iDose TR appears in 1 tracked Healthcare story from February 21, 2026.
Last mentioned: Feb 21, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: medical-devices. Of the tracked stories, 1 of 1 also mention Glaukos Corporation, the most common co-covered peer. The tracked stories average 5 original sources each. iDose TR appears in 1 tracked Healthcare story from February 21, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering iDose TR. Shared-story counts are live from our verified record — not editorial picks.
Q4 2025 Earnings
Both companies report record performance and optimistic 2026 outlooks.
Payer Milestone
Talkspace surpasses 140 million covered lives through payer partnerships.
Talkspace Profitability
Talkspace achieves its first full quarter of adjusted EBITDA profitability.
Commercial Launch
Initial rollout of iDose TR begins in the U.S. market with targeted accounts.
iDose TR FDA Approval
Glaukos receives landmark approval for its travoprost intracameral implant.
Glaukos Corporation and Talkspace, Inc. reported strong Q4 2025 financial results, highlighting a successful transition toward high-margin, recurring revenue models. Glaukos saw significant gains from its iDose TR launch, while Talkspace solidified its position as a profitable, payer-led behavioral health leader.
Source: finance.yahoo.com · finance.yahoo.com
iDose TR is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
